Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/41624
Title: | Permanent pacemaker implantation and left bundle branch block with self-expanding valves - a SCOPE 2 subanalysis | Authors: | Pellegrini, Costanza Garot, Philippe Morice, Marie-Claude Tamburino, Corrado Bleiziffer, Sabine Thiele, Holger Scholtz, Smita Schramm, Rene Cockburn, James Cunnington, Michael Wolf, Alexander Barbanti, Marco Tchetche, Didier Pagnotta, Paolo Gilard, Martine Bedogni, Francesco Van Belle, Eric Vasa-Nicotera, Mariuca Chieffo, Alaide BOGAERTS, Kris Hengstenberg, Christian Capodanno, Davide Joner, Michael Neumann, Franz-Josef |
Issue Date: | 2023 | Publisher: | EUROPA EDITION | Source: | EuroIntervention, 18 (13) , p. E1077 - E1087 | Abstract: | Background: No detailed data on left bundle branch block (LBBB) and permanent pacemaker implantation (PPI) exist from randomised clinical trials comparing the ACURATE neo and CoreValve Evolut devices. Aims: Our aim was to assess the incidence and impact of new LBBB and PPI with self-expanding prostheses from a powered randomised comparison. Methods: From the SCOPE 2 trial, 648 patients with no previous pacemaker were analysed for PPI at 30 days, and 426 patients without previous LBBB were adopted for analysis of LBBB at 30 days. Results: At 30 days, 16.5% of patients required PPI; rates were higher in CoreValve Evolut compared to ACURATE neo recipients (21.0% vs 12.3%; p=0.004). Previous right bundle branch block (odds ratio [OR] 6.11, 95% confidence interval [CI]: 3.19-11.73; p < 0.001) was associated with an increased risk of PPI at 30 days, whereas the use of the ACURATE neo (OR 0.50, 95% CI: 0.31-0.81; p=0.005) was associated with a decreased risk. One-year mortality was similar in patients with and without new PPI. A total of 9.4% of patients developed persistent LBBB at 30 days, with higher incidences in CoreValve Evolut recipients (13.4% vs 5.5%; p=0.007). New LBBB at 30 days was associated with lower ejection fraction at 1 year (65.7%+/- 11.0 vs 69.1%+/- 7.6; p=0.041). Conclusions: New LBBB and PPI rates were lower in ACURATE neo compared to CoreValve Evolut recipients. The ACURATE neo valve was associated with a lower risk of PPI at 30 days. No effect on 1-year mortality was determined for PPI at 30 days, while LBBB at 30 days was associated with reduced ejection fraction at 1 year. | Notes: | Joner, M (corresponding author), Deutsch Herzzentrum Munich, Klin Herz & Kreislauferkrankungen, Lazarettstr 36, D-80636 Munich, Germany. joner@dhm.mhn.de |
Keywords: | aortic stenosis;atrio-ventricular block;femoral | Document URI: | http://hdl.handle.net/1942/41624 | ISSN: | 1774-024X | e-ISSN: | 1969-6213 | DOI: | 10.4244/EIJ-D-22-00558 | ISI #: | 001068623400002 | Rights: | Europa Digital & Publishing 2023. All rights reserved. | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
EIJ-D-22-00558_Pellegrini.pdf Restricted Access | Published version | 758.79 kB | Adobe PDF | View/Open Request a copy |
ACFrOgCEQuhHKWL9aAvf_zYmEx5sQM9Bf8S1-awGhdv5DAEAnotTAp4mIyYFsSKt89o4xsVFW4.pdf | Peer-reviewed author version | 784.59 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.